Aarti Drugs (AARTIDRUGS)
Slow GrowerFairStock Score: 40/100 — MIXED
Score breakdown: P/E: 2/3 · ROCE: 1/2 · Growth: 1/2 · Dividend: 0/1
Key Financials
| Current Price | ₹416.35 |
| Market Cap | ₹3,800.03 Cr |
| P/E Ratio | 19.88 |
| ROCE | 13.09% |
| ROE | 16.02% |
| Dividend Yield | 0.48% |
| Profit Growth | 4.54% |
| Debt/Equity | 0.37 |
| Sales Growth | 20.39% |
| Promoter Holding | 55.03% |
| 52-Week Range | ₹318.95 — ₹534 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹169.79 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
This is the kind of stock that makes me ask whether I am buying a great enterprise or merely a reasonable one. Aarti Drugs is a pharmaceutical company, and the numbers tell me it is decent, but not special. The return on equity is 16.02%, and the return on capital employed is 13.09%. That is respectable, yet it is not the kind of return that screams pricing power or a deep moat. The balance sheet is okay: debt to equity is 0.39, and the Piotroski F-Score of 7/9 suggests the fundamentals are improving or at least holding up. Promoters hold 55.03%, so my interests are tied to people who have skin in the game.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer